The optimal management of patients with locally advanced recto-sigmoid cancer is unclear. Using the National Cancer Database, we assessed patterns of care and outcomes associated with upfront surgery versus neoadjuvant chemoradiation followed by surgery. Although neoadjuvant chemoradiation was used in a small percentage of patients, its use was associated with more complete resections, a robust pathologic complete response rate, and improved overall survival. Introduction: The optimal management of locally advanced recto-sigmoid cancer is unclear. Although some experts advocate for upfront surgery, others recommend neoadjuvant chemoradiation followed by surgery. We used the National Cancer Database to characterize patterns-of-care and overall survival (OS) associated with these treatment strategies. Patients and Methods: Patients with clinical stage II or III recto-sigmoid cancer who underwent surgery with or without adjunctive chemotherapy and/or radiotherapy from 2006 to 2014 were identified, and dichotomized into: (1) upfront surgery, and (2) neoadjuvant chemoradiation cohorts. Patterns-of-care were assessed using multivariable logistic regression. The association between neoadjuvant chemoradiation use and OS was assessed using Cox proportional hazards analysis with propensity score-matching. Results: Of 9313 identified patients, 6756 (73%) underwent upfront surgery and 2557 (27%) received neoadjuvant chemoradiation. Treatment at academic facilities and higher clinical T stage were predictors of neoadjuvant chemoradiation use. Compared with upfront surgery, neoadjuvant chemoradiation resulted in fewer positive circumferential resection margins (384 [11%] patients vs. 108 [8%] patients; P ¼ .001), and 478 [18.7%] patients achieved a pathologic complete response at surgery. In propensity score-matched analysis, neoadjuvant chemoradiation use was associated with improved OS (hazard ratio, 0.79; 95% confidence interval, 0.69-0.90) compared with upfront surgery; 5-year estimated OS was 77.0% versus 72.0%, respectively. The improvement in OS persisted in landmark analysis of patients who survived at least 12 months. Conclusion: Only a small percentage of patients with locally advanced recto-sigmoid cancer receive neoadjuvant chemoradiation even though its use might result in improved OS relative to upfront surgery. Prospective research is warranted to validate and standardize therapeutic strategies in patients with recto-sigmoid cancer.
Introduction
Colorectal cancer is the fourth most common malignancy in the United States, accounting for more than 50,000 deaths annually. 1 Approximately 10% of colorectal cancers arise at the recto-sigmoid junction, which links the distal sigmoid colon to the upper rectum. 2 The optimal management of recto-sigmoid cancer is unclear with some guidelines advocating for treatment of these cancers as colon cancers, 3, 4 others recommending treatment as rectal cancers, and yet others suggesting an individualized approach. 6 This distinction is important in patients with locally advanced disease, because the treatment strategy for colon cancer (upfront surgery with or without adjuvant chemotherapy) differs significantly from that for rectal cancer (neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy). Multiple factors have contributed to the lack of clarity in the management of recto-sigmoid cancer. First, there is limited evidence to inform practice because of a paucity of dedicated research on cancers of the upper rectum. Second, the anatomic definition of the rectum varies across the literature, resulting in uncertainty when interpreting studies, and when staging recto-sigmoid tumors. 7 Third, because the upper rectum is partially encased by peritoneum, in contrast to the extraperitoneal mid-to low rectum, 8 there are concerns that radiotherapy might not be feasible or might be too toxic in this region. 9 Finally, evidence regarding the benefit of radiotherapy in the treatment of upper rectal cancers is inconsistent and conflicting. [10] [11] [12] Outcomes in patients with recto-sigmoid cancer have not previously been investigated in a rigorous manner. To address this shortcoming, we used the National Cancer Database (NCDB) to assess patterns of care and outcomes associated with treatment.
Because of the controversy regarding optimal therapy, we hypothesized that there would be significant variation in the management of patients with locally advanced recto-sigmoid cancer.
Patients and Methods

Data Source
The study population was identified from the NCDB, a national cancer registry jointly sponsored by the American College of Surgeons and the American Cancer Society that draws upon hospital registry data from more than 1500 Commission on Cancer (CoC)-accredited facilities in the United States. The data set captures more than 70% of incident cancers in these regions and comprises more than 34 million unique cancer cases. 13 
Study Population
Inclusion criteria (Figure 1 ) consisted of patients 18 years of age and older with nonmetastatic, American Joint Committee on Cancer seventh edition clinical stage II or III recto-sigmoid junction adenocarcinoma who underwent definitive surgery with or without perioperative radiation and/or chemotherapy. The recto-sigmoid junction is coded as a unique site from other colorectal cancers in the NCDB, and is identified by International Classification of 
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Diseases for Oncology code C19.9. Besides this classification, we lacked further information regarding how tumors were staged. Patients who received radiotherapy to sites outside the pelvis were excluded as were those who received <45 Gy or >60 Gy because this dose range encompasses commonly used long-course preoperative or postoperative radiotherapy doses for rectal cancer. Patients who received short-course preoperative radiotherapy (25 Gy in 5 fractions), an uncommon but acceptable treatment approach in North America, comprised <1% of the study population and were excluded to reduce heterogeneity in the study population. Finally, patients who died within 30 days of surgery (n ¼ 192; 168 and 24 in the upfront surgery and neoadjuvant chemoradiation cohorts, respectively) were excluded to allow for assessment of therapeutic strategies in patients healthy enough to tolerate surgery.
Patient Cohorts and Variables
The overall study population was dichotomized into the following cohorts: (1) upfront surgery with or without adjuvant therapy; and (2) neoadjuvant chemoradiation followed by surgery with or without adjuvant chemotherapy. This dichotomization was chosen because it reflects the first therapeutic decision that providers make in the management of these patients. Covariates examined included sex, age, race, population density of patient residence (metropolitan, urban, or rural), treatment facility geographic location, facility type (nonacademic or academic), distance to facility, insurance coverage, educational attainment (percentage of population in the patient's ZIP code without a high school degree), income (median income in the patient's ZIP code), Charlson/Deyo comorbidity score, 14 tumor histology, size, grade, clinical T and N stage, pathologic T and N stage, proximal/distal surgical margin status, circumferential resection margin status, and year of treatment.
End Points
The primary end point was overall survival (OS), defined as time from diagnosis until death or last follow-up. Additionally, we assessed patterns-of-care associated with treatment of recto-sigmoid cancer.
Statistical Analysis
Baseline characteristics were compared using the Pearson c 2 test.
A multivariable logistic regression model was fitted using stepwise selection and a univariable inclusion criterion of P < .1 to assess the independent effects of covariates on the likelihood of receipt of neoadjuvant chemoradiation. Only covariates that would have been known at the time of recommendation of initial treatment were eligible for inclusion in the regression model. The KaplaneMeier estimator and the log rank tests were used to compare OS between cohorts. Variables trending toward significance (P < .1) in univariable analysis were included in multivariable Cox proportional hazards models to calculate adjusted hazard ratios (HRs) for death to assess the independent effect of receipt of neoadjuvant chemoradiation on OS. Two sequential Cox models were used-in the first model, only covariates that would have been known at the time of recommendation of initial treatment were included; in the second model, previously included variables as well as pathologic variables (pT stage, pN stage, surgical margin status) and receipt of adjuvant chemotherapy were included. These sequential models were used to assess if the decreased hazard of death that was present in the first model could be accounted for by differences in postsurgery variables between cohorts. Patients treated in 2014 were not included in survival analyses because of insufficient follow-up data.
To more robustly account for baseline differences between cohorts, a propensity score was calculated for each patient using logistic regression, 15 which estimated the probability of receipt of neoadjuvant chemoradiation. Using the propensity scores, a matched cohort of 4400 patients (all 2200 patients in the neoadjuvant chemoradiation cohort matched with 2200 patients in the upfront surgery cohort) was identified using 1-to-1 nearest neighbor matching without replacement. Absolute standardized differences of <0.1 between baseline covariates after matching were accepted as a measure of adequate balance. A Cox survival analysis was then repeated on the matched cohort. Landmark analysis was performed on patients surviving at least 12 months after diagnosis to account for potential immortal time bias associated with receipt of neoadjuvant or adjuvant therapies. 16 Finally, the study comparison was assessed in clinical stage II and stage III patients separately to determine if the benefit associated with neoadjuvant chemoradiation persisted in each stage.
A 2-tailed P value < .05 was considered statistically significant. Bonferroni adjustment was applied to account for multiple testing in subset analysis. Statistical analyses were performed using Stata SE, version 14.0 (Stata Corp, College Station, TX).
Results
Patient Characteristics
Of the 9313 patients who met study inclusion criteria 6756 (73%) underwent upfront surgery and 2557 (27%) received neoadjuvant chemoradiation. In the upfront surgery cohort, 1227 (18%) patients received adjuvant chemoradiation whereas 2426 (36%) patients received adjuvant chemotherapy. In the neoadjuvant chemoradiation cohort, 888 (35%) patients received adjuvant chemotherapy. The median age of the cohort was 63 years (interquartile range [IQR], 53-73 years). Most patients were male (n ¼ 5361, 58%), white (n ¼ 7404, 80%), received treatment at nonacademic facilities (n ¼ 6143, 66%), and presented with clinical stage II disease (n ¼ 5047, 54%; Table 1 ).
Factors Associated with Receipt of Neoadjuvant Chemoradiation
In multivariable analysis (Table 2 ), treatment at academic facilities (odds ratio [OR], 1.27; 95% confidence interval [CI], 1.13-1.43; P < .001) and higher clinical T stage (cT4 vs. cT1; OR, 12.3; 95% CI, 7.57-20.1; P < .001) were associated with an increased likelihood of receipt of neoadjuvant chemoradiation. Conversely, female sex, older age, greater comorbidity, and larger tumor size were statistically significantly associated with a decreased likelihood of neoadjuvant chemoradiation use. The proportion of patients who received neoadjuvant chemoradiation over the study period increased from 24.7% in 2006 to 33.1% in 2014 (P < .001; Figure 2 ).
Pathologic Characteristics
In patients with a documented circumferential resection margin status (n ¼ 4940), patients treated with neoadjuvant chemoradiation
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Overall Survival
Median follow-up time in the overall cohort was 42 months (IQR, 24-63 months). Estimated 5-year OS was 65.5% in the upfront surgery cohort and 77.0% in the neoadjuvant chemoradiation cohort overall ( Figure 3A) , and 72.0% versus 77.0% in the matched cohort, respectively ( Figure 3B ).
In multivariable analysis (Table 3) , receipt of neoadjuvant chemoradiation was associated with improved OS relative to upfront surgery (HR, 0.76; 95% CI, 0.68-0.86; P < .001). Other independent predictors of improved OS were female sex, Hispanic relative to white race, and higher income status. Conversely, older age, greater comorbidity, mucinous or signet-ring histology relative to adenocarcinoma, cT4 versus cT1 disease, and cN2 versus cN0 status were statistically significantly associated with worse OS.
In the propensity score-matched cohort, receipt of neoadjuvant chemoradiation remained associated with improved OS (HR, 0.79; 95% CI, 0.69-0.90; P < .001; Table 3 ). The OS benefit associated with neoadjuvant chemoradiation persisted in landmark analysis of patients surviving at least 12 months (HR, 0.82; 95% CI, 0.72-0.93; P ¼ .002), and when patients were stratified according to clinical stage (Supplemental Table 1 ).
When factors potentially influenced by neoadjuvant therapy such as pathologic T stage, N stage, distal/proximal surgical margin status, and circumferential margin status, as well as receipt of adjuvant chemotherapy were included in the multivariable Cox model, the survival benefit associated with neoadjuvant chemoradiation decreased in magnitude but remained statistically significant (HR, 0.87; 95% CI, 0.77-0.99; P ¼ .03).
Discussion
We show an association between receipt of neoadjuvant chemoradiation and improved OS in a cohort of 9313 patients with stage II or III recto-sigmoid cancer. In addition, a patterns-of-care assessment revealed low rates of neoadjuvant chemoradiation use, and variability in the treatment strategy for patients with rectosigmoid cancer, which stands in contrast to the established treatment paradigms for patients with locally advanced sigmoid and rectal cancers. To our knowledge, this is the most comprehensive study to date to investigate treatment patterns and outcomes in patients with recto-sigmoid cancer.
There is a general perception that radiotherapy might not be appropriate for treatment of upper rectal and recto-sigmoid tumors because of the partially intraperitoneal location of these segments of bowel. Arguments against radiotherapy use include the close proximity of the small bowel to potential radiation volumes, the increased mobility of intraperitoneal structures, and the possibility that cancers of the intraperitoneal rectum behave more like colon cancers for which the goal of therapy is to reduce the risk of distant metastases rather than local recurrence. 4, 5 The overall low rate of use of radiotherapy in our cohort lends support to the presence of such perceptions. Data supporting omission of radiotherapy in recto-sigmoid cancer management comes from the Dutch rectal cancer study, which included a subgroup analysis of the risk of rectal cancer recurrence on the basis of tumor location. 10 Results showed that patients with tumors located 10.1 to 15 cm from the anal verge did not experience an improvement in local control with preoperative radiotherapy, in contrast to those with more distal tumors. A shortcoming of this trial was the use of flexible endoscopy to localize tumors, which might overestimate the distance of the tumor to the anal verge. 17 With inaccurate staging, it is conceivable that some misclassification of tumor site occurred, and thereby masked a potential benefit to radiotherapy. Moreover, an update of this trial showed a benefit to preoperative radiotherapy when distance from the anal verge was analyzed as a continuous variable. 18 To this end, the results of this study should be interpreted with caution and its role in informing practice warrants re-evaluation. In contrast, other data lend support for use of preoperative radiotherapy. Subgroup analyses of the German rectal cancer study showed no difference in local control between cancers of the upper third of the rectum and the middle third. 11 In the Medical Research Council (MRC)-07 study, use of preoperative radiotherapy in patients with locally advanced upper rectal cancers resulted in a 1.2% local recurrence rate as opposed to a 6.2% local recurrence rate in patients who received selective postoperative chemoradiation. 12 Because no randomized data exist for recto-sigmoid cancers specifically, these aforementioned rectal cancer trials serve as the best available evidence to guide treatment decisions. 
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A major obstacle to the development of a standard treatment approach for recto-sigmoid cancer has been the variation in definitions of what constitutes rectal cancer. Major North American guidelines define rectal cancer as a tumor located within 12 cm of the anal verge using endoscopy; above 12 cm, tumors are often managed as colon cancer. 3, 19 In contrast, the Union for International Cancer Control Tumor, Node, Metastases classification system considers lesions up to 16 cm from the anal verge to be rectal cancer. To improve management of recto-sigmoid cancer, we propose standardizing the localization of the recto-sigmoid by using more objective criteria than an arbitrary division of the rectum using centimeter criteria. Emerging data suggest that using a crosssectional imaging landmark such as the anterior peritoneal reflection to classify patients as having upper versus mid or low rectal cancer might improve multidisciplinary care of rectal cancer. 21 With this method, rectal tumors above the peritoneal reflection might be treated as intraperitoneal rectal tumors whereas those below the peritoneal reflection could be treated as extraperitoneal rectal tumors. Such an approach would reduce subjectivity regarding tumor location and would facilitate comparisons between trials.
In the overall cohort, we report a 24% decreased hazard of death associated with receipt of neoadjuvant chemoradiation. This survival benefit was partially attributable to tumor downstaging and a lower positive circumferential margin rate that resulted from neoadjuvant chemoradiation use, because adjustment for these features in multivariable models resulted in a decrease in magnitude of the previously noted survival benefit. These results are plausible because achievement of complete pathologic response and negative circumferential margin status have been shown to be strong predictors of decreased local recurrence and improved OS in patients with rectal cancer. 22, 23 The pathologic complete response rate was approximately 19% in our cohort, which aligns with complete response rates of approximately 20% from recent rectal cancer literature. [24] [25] [26] Furthermore, there was robust downstaging of clinical disease in patients who received neoadjuvant chemoradiation. Because rectosigmoid cancers appear to respond to neoadjuvant chemoradiation in a manner similar to rectal cancers, these results argue for treating recto-sigmoid cancers as rectal cancers rather than colon cancers.
In addition to conflicting evidence and the lack of a consensus definition of the rectum, other factors contribute to the reluctance to use neoadjuvant chemoradiation. For instance, the mobility of the upper rectum has been cited as a reason to not treat with radiotherapy. However, previous work indicates that the upper rectum might be a relatively immobile target as high as 19 cm from the anal verge. 27 Potential toxicity from irradiation of the small bowel is another frequently cited reason to avoid radiation; although we were unable to assess treatment toxicity in our study, others have reported that radiotherapy to the upper rectum is well tolerated.
9
Despite these favorable results, it is unclear if all patients with stage II or III recto-sigmoid cancer should receive neoadjuvant chemoradiation. In rectal cancer management, it has been suggested that some patients with stage II disease at a lower risk of recurrence might be adequately treated without radiotherapy. 28, 29 The Preoperative Radiation or Selective Preoperative Radiation and Evaluation before Chemotherapy and Total Mesorectal Excision 
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(PROSPECT) trial (Clinicaltrials.gov identifier: NCT01515787) is an open phase III randomized controlled trial that is presently investigating outcomes after omission of preoperative radiotherapy in locally advanced rectal cancer. In our cohort, 581 (15%) patients (data not shown) with clinically node-negative disease who received upfront surgery were found to have node-positive disease postoperatively, indicating that a significant number of patients are clinically understaged, and might benefit from neoadjuvant chemoradiation. This rate of nodal understaging is similar to previous work that showed a 22% rate in patients with cT3N0 rectal cancer. 28 Although patients upstaged after surgery might be treated with adjuvant therapy to minimize risk of recurrence, the superiority of neoadjuvant therapy is clear with regard to toxicity and efficacy. 11 Although a risk of overtreatment also exists, only 365 Our study is subject to certain limitations. First, selection bias might have influenced study results. To minimize such bias, propensity score matching was used to create balance among baseline covariates between cohorts. Although propensity score matching can account for measured confounders, there are a number of unmeasured confounders such as physician practices and patient preferences regarding treatment for which we were unable to account. Second, we were unable to assess disease recurrence, patterns of failure, or toxicity, which are important end points that inform the potential benefit of perioperative therapy. Finally, because we lacked information regarding staging, including distance of tumor from the anal verge, it is possible that inaccuracies in staging resulted in misclassification of patients with regard to type of cancer they had. However, because the study comprised a modern cohort of patients diagnosed from 2006 to 2014 and treated at CoCaccredited facilities in the United States, it is plausible that most patients were staged with standard modern techniques such as rigid sigmoidoscopy or magnetic resonance imaging-based methods.
Conclusion
In summary, we show low rates of neoadjuvant chemoradiation use in patients with locally advanced recto-sigmoid cancer. In addition, our findings support an association between neoadjuvant chemoradiation use and improved OS compared with upfront surgery. This survival benefit might be attributed in part to pathologic downstaging and higher rates of complete resection associated with neoadjuvant treatment. Study limitations notwithstanding, our results suggest that recto-sigmoid cancer should be treated according to a paradigm similar to rectal cancer. Because of the lack of other robust evidence regarding management of recto-sigmoid cancer, these findings might be hypothesis-generating. Further prospective research dedicated to upper rectal cancers is warranted to validate our findings and standardize treatment.
Clinical Practice Points
Because of a paucity of research, the optimal management of patients with recto-sigmoid junction cancer is unclear. Some experts advocate for treatment of these cancers as colon cancer with upfront surgery, whereas others recommend treatment as rectal cancer with neoadjuvant chemoradiation followed by surgery.
Inconsistent definitions of the recto-sigmoid junction among major guidelines, and the lack of a standardized approach to localization of this segment of bowel have contributed to the controversy regarding optimal management. This study used the NCDB to characterize national treatment patterns in the management of recto-sigmoid cancer, and to compare the effectiveness of upfront surgery versus neoadjuvant chemoradiation followed by surgery. Only 27% of the study cohort was treated with neoadjuvant chemoradiation whereas the others received upfront surgery with or without adjuvant therapy. Treatment at academic facilities and a higher clinical T stage were predictors of receipt of neoadjuvant chemoradiation. Use of neoadjuvant chemoradiation resulted in fewer positive circumferential resection margins compared with upfront surgery, and 18.7% of patients experienced a pathologic complete response at the time of surgery. Neoadjuvant chemoradiation use was also associated with a 5% improvement in OS at 5 years. Although this study is limited by its retrospective design, the findings suggest that use of neoadjuvant chemoradiation is an effective treatment approach for patients with recto-sigmoid cancer. Because of the lack of other evidence on the subject, the results of this study are hypothesis-generating and warrant prospective validation.
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